Restart Life Sciences Corp. NMLSF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score

46/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Restart Life Sciences Corp. (NMLSF) trades at a trailing P/E of 4.5. Trailing earnings yield is 22.17%.

Criteria proven by this page:

VALUE (100/100, Pass) — P/E is below market average (4.5); earnings yield beats bond yields (22.17%).
Trailing Earnings Yield 22.17% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.

Overall SharesGrow Score: 43/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

46/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

Proven by this page

—

FUTURE

N/A

No coverage

✗

PAST

25/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

MOAT

46/100

→ Income

GROWTH

58/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — NMLSF

Valuation Multiples

P/E (TTM)4.5

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.00

EV/EBITDA0.0

Per Share Data

EPS (TTM)$0.01

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings Yield22.17%

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2015	$-0.77	$0.00	$-689.15K	-
2016	$-1.50	$0.00	$-2.08M	-
2017	$-0.84	$0.00	$-1.87M	-
2018	$-1.21	$0.00	$-3.57M	-
2019	$-0.44	$7.19K	$-1.4M	-19439.5%
2020	$-4.54	$11.47K	$-23.25M	-202658.5%
2021	$-0.24	$0.00	$-2.68M	-
2022	$-0.18	$0.00	$-2.47M	-
2023	$-0.08	$25.41K	$-1.22M	-4819.6%
2024	$0.01	$0.00	$224.75K	-